Day One
Thursday July 16, 2025
8:00 am Registration & Coffee
8:50 am Chair’s Opening Remarks
Harnessing Real-World Evidence to Evaluate Adherence and Persistence to Obesity Therapeutics to Inform Payers
9:00 am Examining Real-World Persistence & Adherence to GLP-1s to Inform Payers & Improve Coverage
Synopsis
- Uncovering data-driven insights into actual patient behavior with GLP-1 therapies, highlighting factors influencing adherence and persistence beyond clinical trial settings, to demonstrate the practical challenges and opportunities for improved patient management
- Showcasing how real-world data can be used to assess the long-term economic impact of GLP-1s, aiding payers in value-based purchasing negotiations and demonstrating the financial benefits of sustained treatment
- Exploring how real-world adherence data can guide the development of tailored patient support programs and interventions, leading to improved outcomes and justifying broader payer coverage by demonstrating enhanced patient benefit and treatment efficacy
9:30 am Examining Real-World Persistence & Adherence to GLP-1s to Inform Formulary Decisions for Pharmacy Benefit Managers
Synopsis
- Analysing current GLP-1 patients to understand trends and in adherence and persistence in taking the drug to evaluate whether coverage is beneficial
- Assessing cost effectiveness of different products to aid negotiations between manufacturer value-based purchasing agreements
- Harness adherence data to understand the needs of obesity care management programs to improve standard of care for patients
10:00 am Panel Discussion – Harnessing Real-World Data to Evaluate Coverage Criteria & Consider the Current Clinical Management Strategies for Obesity & Related Conditions
Synopsis
- Reviewing the current coverage for obesity treatments including lifestyle interventions, medication, and surgery to uncover limitations and inconsistencies
- Discussing the need to move beyond simple cost-effectiveness analysis and leveraging RWD to assess the broader value of obesity treatments such as long-term health outcomes
- Addressing comorbidities to highlight the importance of considering related conditions and using RWD to understand the complex links between these conditions to optimize treatment strategies
10:30 am Speed Networking
Synopsis
Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative market access professionals in the obesity, cardiovascular, renal and metabolism, cardiovascular, renal and metabolism field. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the policy and press releases.
11:15 am Morning Break & Networking
Understanding Anti-Obesity Medication Coverage from a State Government Payers Perspective
11:30 am Understanding the Road to Coverage for GLP-1s for State Payers
Synopsis
- Exploring the factors, stakeholders, and coverage options available to state payers
- Discussing strategies for managing costs and maximising value of AOEs to ensure value is clearly demonstrated to state decision-makers
- Analysing the impact of Medicaid and Medicare policies on state payer decisions
12:00 pm Uncovering Medicare Formulary Restrictions for Diabetes & Obesity Patients to Identify Treatment Gaps & Work Towards Increased Coverage
Synopsis
- Discussing Benefits of GLP-1s related to the decrease in cardiovascular events, heart failure hospitalizations and kidney disease progression
- Outlining the American Diabetes Associations updated guidelines to increase the use of GLP-1s as potential first -line options for patients with cardio-renal conditions
- Navigating formulary restrictions such as step therapy and prior authorizations to increase patient access to GLP-1s
12:30 pm Uncovering the Benefits of State Wide Prescription Drug Affordability Board’s to Reduce High Costs Associated with GLP-1s for Diabetes
Synopsis
- Detailing the specific powers and mandate of the Maryland Prescription Drug Affordability Board (PDAB), highlighting their recent or ongoing focus on the cost of GLP-1 receptor agonists, given their significant utilization and budget impact
- Explaining the processes, the Maryland PDAB employs to review the cost of GLP-1s, including data analysis, stakeholder engagement, and the potential mechanisms they might utilize to recommend or set upper payment limits or negotiate supplemental rebates
- Discussing the anticipated effects of the Maryland PDAB’s actions on GLP-1 pricing for patients, payers (including the state Medicaid program), healthcare providers, and pharmaceutical manufacturers, and consider the potential for Maryland’s approach to influence other states or federal policies
1:00 pm Lunch & Networking
2:00 pm Panel Discussion: Discussing the Potential Impact of GLP-1 Coverage on State & Federal Budgets & Healthcare Systems
Synopsis
- Highlighting the prevalence of diabetes and obesity in lower income families that rely on public healthcare systems
- Discussing the potential for AOMs to improve public health outcomes and reduce the long-term costs of treatment associated with the end-stage results of obesity such as MASH and heart disease
- Understanding the direct cost of GLP-1 coverage per member considering coverage tiers, utilization rate and pharmaceutical spend
- Examining strategies such as value-based pricing agreements and manufacturer negotiations to reduce cost and add value too state decision makers
2:30 pm Roundtable Discussion – Effectively Integrating Real-World Evidence for Holistic Obesity Management to Improve Value Proposition for Private, Commercial & State Payers
Synopsis
- Predictive Data Modelling to Inform Future
- Quantifying Return on Investment for Payers
- Scaling & Sustaining Holistic Obesity Management
3:00 pm Afternoon Refreshments & Networking
Maximizing Market Access Strategies in Wider Cardiovascular, Renal & Metabolism Indications to Evaluate Pricing Models & Strategies for MASH & Cardiovascular Indications
3:30 pm Uncovering the Success of Dual Brand Strategy for Anti-Obesity Medications: Lessons Learnt from the GLP-1 Boom to Inform Future Strategies
Synopsis
- Defining what constitutes a dual brand strategy in the context of GLP-1 medications, considering separate brands for different indications, different dosages, and different marketing strategies
- Understanding the core motivations behind dual brand strategies for anti-obesity medications
- Analyzing the risks and benefits of dual brand strategy: why has this worked so well for Eli Lilly and Novo Nordisk
- Evaluating the segmentation of patient populations, treatment regimens, clinical profiles, and endpoints for each brand
- Understanding the impact of different dosing strategies on patient outcomes and market perception
4:00 pm Effectively Working with Government Healthcare Programs to Improve Coverage & Access to Liver Disease Treatments
Synopsis
- Navigating the FDAs regulatory process for liver disease treatments and addressing the safety concerns and challenges with the liver biopsy process
- Examining the complex relationship between payer policies and patient out-of-pocket expenses for AOMs, and how this dynamic can lead to drug shortages and restricted access for individuals with end-stage conditions such as MASH
- Highlighting the importance of patient representation during approval processes to inform market access strategies
4:30 pm Panel – Lessons Learnt from Obesity & Diabetes to Inform Market Access Strategies for Wider Cardiometabolic Indications
Synopsis
- Understanding common barriers to patient access and affordability for treatments in these areas to consider how cost-sharing arrangements can be effectively navigated
- Understanding how availability of existing treatments and the pipeline of new therapies differ across CVRM disease areas effects market access dynamics
- Uncovering best practices in market access that have been applied in one disease area that could be applied to others to share lessons leant and avoid future bottlenecks